Twist Bioscience (TWST) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Feb, 2026Opening remarks and agenda
The meeting was called to order by the Lead Independent Director, who introduced the board members and business team in attendance.
The agenda included formal business as set forth in the notice and proxy materials, followed by a Q&A session for validated stockholders.
Corporate governance
The record date for voting was set as December 26, 2025, with all required notices and materials mailed to stockholders.
Kathy Blackwell of Broadridge was appointed as Inspector of Election, having taken the customary oath.
A quorum was established with proxies representing 91.81% of outstanding shares.
Shareholder proposals
Three proposals were presented: election of three directors, advisory approval of executive compensation, and ratification of the independent auditor.
The board recommended approval of all three proposals.
Latest events from Twist Bioscience
- Silicon-based DNA synthesis and automation fuel rapid growth, with profitability in sight.TWST
46th Annual William Blair Growth Stock Conference2 Jun 2026 - Revenue and margin growth accelerate as automation and AI drive innovation and scale.TWST
Corporate presentation2 Jun 2026 - AI-driven discovery, automation, and new products are fueling rapid growth and margin expansion.TWST
Investor Day 202622 May 2026 - AI-driven workflows, new platforms, and innovation fuel growth and margin expansion.TWST
Barclays 28th Annual Global Healthcare Conference7 May 2026 - Q2 revenue up 19% to $110.7M, gross margin 51.6%, FY26 guidance raised, breakeven in sight.TWST
Q2 20265 May 2026 - Automation, AI, and new products drive rapid growth and margin expansion in high-throughput markets.TWST
Leerink Global Healthcare Conference 202611 Mar 2026 - AI and MRD growth, automation, and innovation drive margin expansion and market leadership.TWST
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - B-Body® platform accelerates bispecific antibody discovery, driving growth and profitability.TWST
Corporate presentation17 Feb 2026 - Q1 FY26 revenue up 17% to $103.7M, gross margin 52%, FY26 outlook raised, net loss narrowed.TWST
Q1 20262 Feb 2026